Volpara Health Technologies Ltd. (VPAHF) Receives a Buy from Bell Potter

According to, Hester is a 1-star analyst with an average return of -7.7% and a 33.3% success rate. Hester covers the Healthcare sector, focusing on stocks such as Paradigm Biopharmaceuticals Ltd., Pro Medicus Limited, and Nanosonics Limited.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Volpara Health Technologies Ltd. with a $0.88 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Volpara Health Technologies Ltd.’s latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $0. In comparison, last year the company had a net profit of $0.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Volpara Health Technologies Ltd. engages in selling the VolparaEnterprise software, which is a cloud-based breast imaging analytics product. Its products include VolparaDensity and VolparaEnterprise DDP. The company was founded by Martin Yaffe and Nico Karssemeijer in 2009 and is headquartered in Wellington, New Zealand.

Read More on VPAHF:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed